296 related articles for article (PubMed ID: 18827913)
1. Antiplatelet drugs in cardiological practice: established strategies and new developments.
Krötz F; Sohn HY; Klauss V
Vasc Health Risk Manag; 2008; 4(3):637-45. PubMed ID: 18827913
[TBL] [Abstract][Full Text] [Related]
2. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
[TBL] [Abstract][Full Text] [Related]
3. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
[TBL] [Abstract][Full Text] [Related]
4. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.
Wiviott SD; Braunwald E; McCabe CH; Horvath I; Keltai M; Herrman JP; Van de Werf F; Downey WE; Scirica BM; Murphy SA; Antman EM;
Lancet; 2008 Apr; 371(9621):1353-63. PubMed ID: 18377975
[TBL] [Abstract][Full Text] [Related]
5. Antiplatelet agents.
Varon D; Spectre G
Hematology Am Soc Hematol Educ Program; 2009; ():267-72. PubMed ID: 20008209
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of platelet activation and aggregation.
Ahrens I; Bode C; Peter K
Handb Exp Pharmacol; 2005; (170):443-62. PubMed ID: 16596810
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the degree of platelet aggregation inhibition with prasugrel versus clopidogrel and clinical outcomes in patients with unprotected left main disease treated with everolimus-eluting stents.
Migliorini A; Valenti R; Parodi G; Marcucci R; Abbate R; Carrabba N; Gensini GF; Antoniucci D
Am J Cardiol; 2013 Dec; 112(12):1843-8. PubMed ID: 24063827
[TBL] [Abstract][Full Text] [Related]
8. [Antiplatelet agents].
Steg G
Bull Acad Natl Med; 2013 Feb; 197(2):375-87; discussion 387-8. PubMed ID: 24919367
[TBL] [Abstract][Full Text] [Related]
9. New thoughts on strategies for modulating platelet function through the inhibition of surface receptors.
Nurden AT
Haemostasis; 1996 Oct; 26 Suppl 4():78-88. PubMed ID: 8979114
[TBL] [Abstract][Full Text] [Related]
10. New perspectives in antiplatelet therapy.
Tello-Montoliu A; Jover E; Rivera J; Valdés M; Angiolillo DJ; Marín F
Curr Med Chem; 2012; 19(3):406-27. PubMed ID: 22335515
[TBL] [Abstract][Full Text] [Related]
11. Rationale for antiplatelet therapy in patients with atherothrombotic disease.
Dormandy JA
Vasc Med; 1998; 3(3):253-5. PubMed ID: 9892519
[TBL] [Abstract][Full Text] [Related]
12. Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study.
Serebruany VL; Midei MG; Meilman H; Malinin AI; Lowry DR
Postgrad Med J; 2006 Jun; 82(968):404-10. PubMed ID: 16754711
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
[TBL] [Abstract][Full Text] [Related]
15. Bedside evaluation of thienopyridine antiplatelet therapy.
Price MJ
Circulation; 2009 May; 119(19):2625-32. PubMed ID: 19451364
[No Abstract] [Full Text] [Related]
16. Platelet-endothelial interactions in atherothrombotic disease: therapeutic implications.
Wilson JM; Ferguson JJ
Clin Cardiol; 1999 Nov; 22(11):687-98. PubMed ID: 10554682
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel.
Schrör K
Vasc Med; 1998; 3(3):247-51. PubMed ID: 9892518
[TBL] [Abstract][Full Text] [Related]
18. Approaching an age of reason with antiplatelet therapy.
Ajani AE; Lefkovits J
Lancet; 2008 Apr; 371(9621):1315-6. PubMed ID: 18424309
[No Abstract] [Full Text] [Related]
19. Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond.
Mousa SA
Curr Pharm Des; 2003; 9(28):2317-22. PubMed ID: 14529393
[TBL] [Abstract][Full Text] [Related]
20. [Clopidogrel in the prevention of stroke].
Nagy V; Fehér J
Orv Hetil; 2004 Dec; 145(51):2563-7. PubMed ID: 15715289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
